# Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

> **NCT01534637** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 22 (actual)

## Conditions studied

- Extrahepatic Bile Duct Cancer
- Nausea
- Vomiting
- Stage II Pancreatic Cancer
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** aprepitant
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** capecitabine
- **DRUG:** fluorouracil
- **PROCEDURE:** radiation therapy
- **OTHER:** questionnaire administration
- **PROCEDURE:** quality-of-life assessment
- **PROCEDURE:** nausea and vomiting therapy
- **PROCEDURE:** management of therapy complications

## Key facts

- **NCT ID:** NCT01534637
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2009-12
- **Final completion:** 2012-08
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-08-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01534637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01534637, "Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01534637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*